Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Search
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Data Science
Revolutionizing research and development with data driven insights
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
Global Top Employer 2023
Global Top Employer 2023
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Systemic sclerosis physician video
In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma
Lamb-shanks video
This succulent, heart dish is packed full of flavour and sure to be a hit with the whole family.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
CPHI Survey
CPHI Survey
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.